HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 5 (2008), Issue 3 (March)

1. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study.
   Lancet, 371(9614): 752-9. [Abstract] [Full-text]
2. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs.
   J Med Virol, 80(4): 565-76. [Abstract] [Full-text]
3. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.
   Hepatology, 47(3): 817-26. [Abstract] [Full-text]
4. Dentistry and the ethics of infection.
   J Med Ethics, 34(3): 184-7. [Abstract] [Full-text]
5. Provider-initiated HIV testing and counseling in health facilities--what does this mean for the health and human rights of pregnant women?
   Dev World Bioeth, 8(1): 23-32. [Abstract] [Full-text]
6. Mandatory HIV testing in pregnancy: is there ever a time?
   Dev World Bioeth, 8(1): 1-10. [Abstract] [Full-text]
7. 'Even if you're positive, you still have rights because you are a person': human rights and the reproductive choice of HIV-positive persons.
   Dev World Bioeth, 8(1): 11-22. [Abstract] [Full-text]
8. Efficient production of HIV-1 viral-like particles in mouse cells.
   Biochem Biophys Res Commun, 368(3): 463-9. [Abstract] [Full-text]
9. Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation.
   Biochem Pharmacol, 75(6): 1370-80. [Abstract] [Full-text]
10. Raltegravir: an integrase inhibitor for HIV-1.
    Expert Opin Investig Drugs, 17(3): 413-22. [Abstract] [Full-text]
11. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G.
    Nature, 452(7183): 116-9. [Abstract] [Full-text]
12. Persistent human immunodeficiency virus-1 antigenaemia affects the expression of interleukin-7Ralpha on central and effector memory CD4+ and CD8+ T cell subsets.
    Clin Exp Immunol, 152(1): 72-80. [Abstract] [Full-text]
13. Decreased serum lipocalin-2 levels in human immunodeficiency virus-infected patients: increase during highly active anti-retroviral therapy.
    Clin Exp Immunol, 152(1): 57-63. [Abstract] [Full-text]
14. HIV increases HCV replication in a TGF-beta1-dependent manner.
    Gastroenterology, 134(3): 803-11. [Abstract] [Full-text]
15. Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database.
    Transplantation, 85(3): 359-68. [Abstract] [Full-text]
16. Long-term follow-up of a heart transplant recipient with documented seroconversion to HIV-positive status 1 year after transplant.
    Am J Transplant, 8(4): 893-6. [Abstract] [Full-text]
17. Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation.
    Cell Host Microbe, 3(3): 158-67. [Abstract] [Full-text]
18. Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes.
    J Clin Microbiol, 46(3): 887-91. [Abstract] [Full-text]
19. Comparison of results obtained with Amplicor HIV-1 DNA PCR test version 1.5 using 100 versus 500 microliters of whole blood.
    J Clin Microbiol, 46(3): 1104-5. [Abstract] [Full-text]
20. Severe necrotizing fasciitis in a human immunodeficiency virus-positive patient caused by methicillin-resistant Staphylococcus aureus.
    J Clin Microbiol, 46(3): 1144-7. [Abstract] [Full-text]
21. Acetylation of conserved lysines in the catalytic core of cyclin-dependent kinase 9 inhibits kinase activity and regulates transcription.
    Mol Cell Biol, 28(7): 2201-12. [Abstract] [Full-text]
22. Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant.
    J Acquir Immune Defic Syndr, 47(4): 403-11. [Abstract] [Full-text]
23. Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B'.
    J Acquir Immune Defic Syndr, 47(4): 412-21. [Abstract] [Full-text]
24. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies.
    Proc Natl Acad Sci U S A, 105(10): 3739-44. [Abstract] [Full-text]
25. Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN.
    Proc Natl Acad Sci U S A, 105(10): 3690-5. [Abstract] [Full-text]
26. Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals.
    J Virol, 82(7): 3561-73. [Abstract] [Full-text]
27. Single-cell, phosphoepitope-specific analysis demonstrates cell type- and pathway-specific dysregulation of Jak/STAT and MAPK signaling associated with in vivo human immunodeficiency virus type 1 infection.
    J Virol, 82(7): 3702-12. [Abstract] [Full-text]
28. IRF-1 is required for full NF-kappaB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancer.
    J Virol, 82(7): 3632-41. [Abstract] [Full-text]
29. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
    J Virol, 82(7): 3261-70. [Abstract] [Full-text]
30. Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy.
    J Virol, 82(7): 3391-404. [Abstract] [Full-text]
31. Otosyphilis in HIV-coinfected individuals: a case series from Toronto, Canada.
    AIDS Patient Care STDS, 22(3): 213-9. [Abstract] [Full-text]
32. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals.
    AIDS Patient Care STDS, 22(3): 233-43. [Abstract] [Full-text]
33. Effect of spatial distribution of T-Cells and HIV load on HIV progression.
    Bioinformatics, 24(6): 855-60. [Abstract] [Full-text]
34. Primary T-lymphocytes rescue the replication of HIV-1 DIS RNA mutants in part by facilitating reverse transcription.
    Nucleic Acids Res, 36(5): 1578-88. [Abstract] [Full-text]
35. Insights into the selective activation of alternatively used splice acceptors by the human immunodeficiency virus type-1 bidirectional splicing enhancer.
    Nucleic Acids Res, 36(5): 1450-63. [Abstract] [Full-text]
36. Inhibitory function of adapter-related protein complex 2 alpha 1 subunit in the process of nuclear translocation of human immunodeficiency virus type 1 genome.
    Virology, 373(1): 171-80. [Abstract] [Full-text]
37. Derivation of infectious HIV-1 molecular clones with LTR mutations: sensitivity to the CD8+ cell noncytotoxic anti-HIV response.
    Virology, 373(1): 30-8. [Abstract] [Full-text]
38. HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation.
    Virology, 373(1): 85-97. [Abstract] [Full-text]
39. Antiretroviral regimens for treatment-experienced patients with HIV-1 infection.
    Expert Opin Pharmacother, 9(5): 687-700. [Abstract] [Full-text]
40. CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides.
    J Antimicrob Chemother, 61(4): 818-26. [Abstract] [Full-text]
41. Forgiveness of non-adherence to HIV-1 antiretroviral therapy.
    J Antimicrob Chemother, 61(4): 769-73. [Abstract] [Full-text]
42. The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication.
    J Antimicrob Chemother, 61(4): 786-91. [Abstract] [Full-text]
43. The utility of fine needle aspiration in HIV positive children.
    Cytopathology, 19(2): 86-93. [Abstract] [Full-text]
44. RNA interference and its therapeutic potential against HIV infection.
    Expert Opin Biol Ther, 8(4): 449-61. [Abstract] [Full-text]
45. Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/- gammac -/- (RAG-hu) mice.
    Virology, 373(2): 342-51. [Abstract] [Full-text]
46. Comparison of anti-viral activity of rhesus monkey and cynomolgus monkey TRIM5alphas against human immunodeficiency virus type 2 infection.
    Virology, 373(2): 447-56. [Abstract] [Full-text]
47. Nef enhances HIV-1 infectivity via association with the virus assembly complex.
    Virology, 373(2): 287-97. [Abstract] [Full-text]
48. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.
    Virology, 373(2): 387-99. [Abstract] [Full-text]
49. Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses.
    Retrovirology, 5: 23. [Abstract] [Full-text]
50. Scope of rapid HIV testing in private nonprofit urban community health settings in the United States.
    Am J Public Health, 98(4): 736-42. [Abstract] [Full-text]
51. Infant feeding in the time of HIV: rapid assessment of infant feeding policy and programmes in four African countries scaling up prevention of mother to child transmission programmes.
    Arch Dis Child, 93(4): 288-91. [Abstract] [Full-text]
52. The spectrum of human immunodeficiency virus-associated cancers in a South African black population: results from a case-control study, 1995-2004.
    Int J Cancer, 122(10): 2260-5. [Abstract] [Full-text]
53. Negative and positive mRNA splicing elements act competitively to regulate human immunodeficiency virus type 1 vif gene expression.
    J Virol, 82(8): 3921-31. [Abstract] [Full-text]
54. Two amino acid substitutions within the first external loop of CCR5 induce human immunodeficiency virus-blocking antibodies in mice and chickens.
    J Virol, 82(8): 4125-34. [Abstract] [Full-text]
55. Modulation of beta-catenin and E-cadherin interaction by Vpu increases human immunodeficiency virus type 1 particle release.
    J Virol, 82(8): 3932-8. [Abstract] [Full-text]
56. Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro.
    J Virol, 82(8): 3997-4006. [Abstract] [Full-text]
57. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing.
    J Virol, 82(8): 3952-70. [Abstract] [Full-text]
58. Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells.
    J Virol, 82(8): 4102-14. [Abstract] [Full-text]
59. Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked.
    J Virol, 82(8): 3834-42. [Abstract] [Full-text]
60. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle.
    Proc Natl Acad Sci U S A, 105(12): 4832-7. [Abstract] [Full-text]
61. Episodic sexual transmission of HIV revealed by molecular phylodynamics.
    PLoS Med, 5(3): e50. [Abstract] [Full-text]
62. Transient-mediated fate determination in a transcriptional circuit of HIV.
    Nat Genet, 40(4): 466-70. [Abstract] [Full-text]
63. High prevalence of HIV infection among rural tea plantation residents in Kericho, Kenya.
    Epidemiol Infect, 136(5): 694-702. [Abstract] [Full-text]
64. The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication.
    PLoS Pathog, 4(3): e1000046. [Abstract] [Full-text]
65. Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage.
    PLoS Pathog, 4(3): e1000033. [Abstract] [Full-text]
66. Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease.
    Am J Pathol, 172(4): 1100-11. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.